Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs)

NCT06926634 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

32

Enrollment

OTHER

Sponsor class

Conditions

High Grade Neuroendocrine Neoplasms

Interventions

DRUG: Zanzalintinib

Sponsor

Washington University School of Medicine

Collaborators

[object Object]